A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

clipboard-pencil

About the study

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Age 12-70 years at screening.
  2. Has a diagnosis of SLE for at least 6 months prior to the screening visit.
  3. Meets the 2019 EULAR/ACR Classification criteria for SLE.
  4. Moderately to severely active SLE defined by the following:

  1. SELENA SLEDAI total score ≥6 points with clinical SLEDAI score ≥4 points at screening;
  2. BILAG organ system scores of at least 1A or 2B at screening.
  3. Clinical SLEDAI score of ≥4 at Day 0 prior to randomization.
  4. At least one positive serologic parameter within the screening period.
  5. Currently receiving at least one of the SOC SLE medications: oral corticosteroid, antimalarial and/or immunosuppressive agent.

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Active lupus nephritis undergoing induction therapy or unstable renal diseases within 12 weeks prior to screening.
  2. Active or unstable neuropsychiatric SLE.
  3. Autoimmune or rheumatic disease other than SLE

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition
Systemic Lupus Erythematosus
Age (in years)
12 - 70
Phase
PHASE3
Participants needed
350
Est. Completion Date
Mar 2, 2027
Treatment type
INTERVENTIONAL

Sponsor
RemeGen Co., Ltd.
ClinicalTrials.gov identifier
NCT05306574
Study number
RC18G001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.